Speqta: Strategic Review Completed
Research Note
2022-03-17
07:53
Redeye retains its positive view on Speqta following the Strategic Review. We believe the significant cash dividend combined with investments in Bidbrain is a balanced low-risk approach that should satisfy most shareholders.
Fredrik Nilsson
Disclosures and disclaimers